Sessilifoline A is primarily studied for its potential neuroprotective effects. It has shown activity in modulating neurotransmitter systems, particularly those involving dopamine and glutamate, suggesting possible applications in neurodegenerative disorders such as Parkinson’s and Alzheimer’s disease. Research indicates it may help reduce neuronal damage caused by oxidative stress and inflammation in the brain. Additionally, it exhibits anxiolytic and sedative properties in preclinical models, making it a candidate for development in treating anxiety and sleep disorders. Its natural origin and bioactivity also make it a lead compound for designing new central nervous system-targeting therapeutics.